Enterococcus faecium.

S. boulardii is a yeast, so antibacterial drugs do not touch it. When the two are given together during a course of antibiotics, the yeast keeps working while the bacterial strain is partly suppressed. The pairing is common in veterinary and human antibiotic-associated stool formulations. Read it as formulation logic supported by mechanism rather than a head-to-head trial.

The two organisms sit in different parts of the gut and use different carbohydrate sources, so they compete less with each other than two similar strains would. Blends are built this way to widen the range of substrate that gets fermented. What that produces in a given person still depends on the diet underneath it. Strain-level effects do not transfer between products.

A live organism needs something to eat once it arrives. Inulin passes undigested to the colon and is fermented by lactic-acid bacteria, which is the basis for pairing it with a probiotic strain in a single product. The combination is a synbiotic by definition rather than by demonstrated outcome. Inulin also causes gas and bloating in a meaningful share of people at higher intakes.

FOS reaches the colon intact and serves as fermentable substrate for the delivered strain. The shorter chain length means fermentation happens more proximally than with long-chain inulin. That is a difference in where the gas appears, not a difference in quality. Tolerance varies widely between people.

Zinc status affects how the intestinal lining repairs itself, and a live organism acts on the luminal side. Two different mechanisms converging on barrier integrity is the rationale for the pairing. It is mechanistic reasoning, not a demonstrated combination effect in people. Zinc at higher chronic doses competes with copper absorption, which matters for long-term use.

Colostrum contributes preformed immune proteins to the lumen while the probiotic contributes a living organism. They are not doing the same thing, which is the reason to combine them. Human data on the specific pairing is thin. The lactoferrin component also binds iron, which is worth knowing if iron is being taken.

Colonocytes run largely on butyrate. A probiotic strain changes fermentation upstream, while supplemental butyrate delivers the end product directly. The two routes overlap, so combining them is duplicative in intent rather than genuinely synergistic. Oral butyrate mostly gets absorbed before the distal colon unless it is protected.

Proteases in an enzyme blend act on protein in the upper gut, and there is a theoretical concern about protease activity against bacterial cell surfaces during co-formulation. Manufacturers usually separate them by coating or delayed release. This is formulation convention worth flagging rather than a demonstrated loss of viability. Ask the maker how the two are kept apart.